注意缺陷多动障碍药物与心血管疾病风险:系统评价与Meta分析
该系统评价与Meta分析纳入19项观察性研究(含14项队列研究),共3 931 532名儿童、青少年和成人(60.9%为男性),来自6个国家或地区,中位随访时间0.25至9.5年(中位1.5年)。合并调整后相对危险度显示,注意缺陷多动障碍药物使用与任何心血管疾病在儿童和青少年(RR 1.18;95%CI 0.91-1.53)、青年或中年成人(RR 1.04;95%CI 0.43-2.48)、老年成人(RR 1.59;95%CI 0.62-4.05)中均无统计学显著关联。兴奋剂(RR 1.24;95%CI 0.84-1.83)和非兴奋剂(RR 1.22;95%CI 0.25-5.97)也均无显著关联。特定心血管结局中,心脏骤停或心律失常(RR 1.60;95%CI 0.94-2.72)、脑血管疾病(RR 0.91;95%CI 0.72-1.15)、心肌梗死(RR 1.06;95%CI 0.68-1.65)均无统计学显著关联。女性患者(RR 1.88;95%CI 0.43-8.24)和已有心血管疾病者(RR 1.31;95%CI 0.80-2.16)中亦无关联。除脑血管疾病分析外,研究间异质性高且显著。作者认为,虽不能排除轻度风险增加,尤其心脏骤停或快速性心律失常风险,但需进一步研究女性、已有心血管疾病患者及长期用药风险。
要点
- 儿童和青少年使用注意缺陷多动障碍药物与任何心血管疾病无统计学显著关联(RR 1.18;95%CI 0.91-1.53)。
- 青年或中年成人(RR 1.04;95%CI 0.43-2.48)和老年成人(RR 1.59;95%CI 0.62-4.05)中亦无统计学显著关联。
- 兴奋剂(RR 1.24;95%CI 0.84-1.83)与非兴奋剂(RR 1.22;95%CI 0.25-5.97)均无显著关联。
- 心脏骤停或心律失常风险无统计学显著关联(RR 1.60;95%CI 0.94-2.72),但不能排除轻度风险增加。
- 女性患者(RR 1.88;95%CI 0.43-8.24)和已有心血管疾病者(RR 1.31;95%CI 0.80-2.16)中无关联,作者认为需进一步研究。
适用人群与场景
- 儿童、青少年和成人注意缺陷多动障碍患者,来自6个国家或地区,共3 931 532名参与者(60.9%为男性)。
- 纳入观察性研究,包括队列研究14项。
研究设计与关键结果
- 研究设计:系统评价与Meta分析,纳入19项观察性研究(其中14项为队列研究),共3 931 532名参与者,来自6个国家或地区,中位随访时间0.25至9.5年(中位1.5年)。
- 主要终点:注意缺陷多动障碍药物使用与任何心血管疾病的合并调整后相对危险度在儿童和青少年中为RR 1.18(95%CI 0.91-1.53),在青年或中年成人中为RR 1.04(95%CI 0.43-2.48),在老年成人中为RR 1.59(95%CI 0.62-4.05),均无统计学显著关联。
- 药物类别:兴奋剂RR 1.24(95%CI 0.84-1.83),非兴奋剂RR 1.22(95%CI 0.25-5.97),均无统计学显著关联。
- 特定心血管结局:心脏骤停或心律失常RR 1.60(95%CI 0.94-2.72),脑血管疾病RR 0.91(95%CI 0.72-1.15),心肌梗死RR 1.06(95%CI 0.68-1.65),均无统计学显著关联。
- 亚组:女性患者RR 1.88(95%CI 0.43-8.24),已有心血管疾病者RR 1.31(95%CI 0.80-2.16),均无统计学显著关联。
- 异质性:除脑血管疾病分析外,研究间异质性高且显著。
证据类型、等级与局限
- 证据类型:系统评价与Meta分析,纳入观察性研究(19项,其中14项队列研究)。
- 研究质量评估采用Good Research for Comparative Effectiveness(GRACE)清单,数据采用随机效应模型合并,报告遵循Meta-analyses of Observational Studies in Epidemiology指南。
- 局限:除脑血管疾病分析外,研究间异质性高且显著;作者指出不能排除轻度风险增加,尤其心脏骤停或快速性心律失常风险;作者认为需进一步研究女性患者、已有心血管疾病患者的心血管风险以及注意缺陷多动障碍药物相关的长期风险。
对床旁实践的改变
- 作者认为,该Meta分析提示注意缺陷多动障碍药物与心血管疾病风险在各年龄组中无统计学显著关联,但不能排除轻度风险增加,尤其心脏骤停或快速性心律失常风险。
- 作者认为,需进一步研究女性患者和已有心血管疾病患者的心血管风险,以及注意缺陷多动障碍药物使用的长期风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Use of attention-deficit/hyperactivity disorder (ADHD) medications has increased substantially over the past decades, but there are concerns regarding their cardiovascular safety.
OBJECTIVE: To provide an updated synthesis of evidence on whether ADHD medications are associated with the risk of a broad range of cardiovascular diseases (CVDs).
DATA SOURCES: PubMed, Embase, PsycINFO, and Web of Science up to May 1, 2022.
STUDY SELECTION: Observational studies investigating the association between ADHD medications (including stimulants and nonstimulants) and risk of CVD.
DATA EXTRACTION AND SYNTHESIS: Independent reviewers extracted data and assessed study quality using the Good Research for Comparative Effectiveness (GRACE) checklist. Data were pooled using random-effects models. This study is reported according to the Meta-analyses of Observational Studies in Epidemiology guideline.
MAIN OUTCOMES AND MEASURES: The outcome was any type of cardiovascular event, including hypertension, ischemic heart disease, cerebrovascular disease, heart failure, venous thromboembolism, tachyarrhythmias, and cardiac arrest.
RESULTS: Nineteen studies (with 3 931 532 participants including children, adolescents, and adults; 60.9% male), of which 14 were cohort studies, from 6 countries or regions were included in the meta-analysis. Median follow-up time ranged from 0.25 to 9.5 years (median, 1.5 years). Pooled adjusted relative risk (RR) did not show a statistically significant association between ADHD medication use and any CVD among children and adolescents (RR, 1.18; 95% CI, 0.91-1.53), young or middle-aged adults (RR, 1.04; 95% CI, 0.43-2.48), or older adults (RR, 1.59; 95% CI, 0.62-4.05). No significant associations for stimulants (RR, 1.24; 95% CI, 0.84-1.83) or nonstimulants (RR, 1.22; 95% CI, 0.25-5.97) were observed. For specific cardiovascular outcomes, no statistically significant association was found in relation to cardiac arrest or arrhythmias (RR, 1.60; 95% CI, 0.94-2.72), cerebrovascular diseases (RR, 0.91; 95% CI, 0.72-1.15), or myocardial infarction (RR, 1.06; 95% CI, 0.68-1.65). There was no associations with any CVD in female patients (RR, 1.88; 95% CI, 0.43-8.24) and in those with preexisting CVD (RR, 1.31; 95% CI, 0.80-2.16). Heterogeneity between studies was high and significant except for the analysis on cerebrovascular diseases.
CONCLUSIONS AND RELEVANCE: This meta-analysis suggests no statistically significant association between ADHD medications and the risk of CVD across age groups, although a modest risk increase could not be ruled out, especially for the risk of cardiac arrest or tachyarrhythmias. Further investigation is warranted for the cardiovascular risk in female patients and patients with preexisting CVD as well as long-term risks associated with ADHD medication use.
参考来源
- Zhang L, Yao H, Li L, et al. Risk of Cardiovascular Diseases Associated With Medications Used in Attention-Deficit/Hyperactivity Disorder: A Systematic Review and Meta-analysis. JAMA Netw Open. 2022. PMID: 36416824. doi:10.1001/jamanetworkopen.2022.43597
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。